CBD and Hemp in the US: Federal Rules, State Laws and What Changes Next

Rules checked: November 4, 2026. Laws and agency guidance can change. This is general information, not legal or medical advice.

Verified November 4, 2026. “Hemp-derived” is not a nationwide permission slip. In the United States, a CBD product can raise separate questions about controlled substances, food and drug regulation, cultivation, retail licensing and transportation. A change to one layer does not automatically change the others.

There is also an important calendar correction: the hemp amendment enacted in November 2025 is not fully effective today. A subsequent law split its implementation between November 12 and December 11, 2026. Describing the entire amendment as already operative—or all of it as starting November 12—would be misleading. [1–3]

CBD, hemp and marijuana are different kinds of terms

CBD, short for cannabidiol, is a cannabinoid: a chemical compound found in cannabis. It is generally described as non-intoxicating, unlike delta-9 THC, the principal compound associated with the cannabis “high.” Non-intoxicating does not mean risk-free, and CBD content alone does not determine a product’s legal classification.

Hemp and marijuana are legal categories applied to cannabis and its derivatives. Under the 2018 federal definition applicable on this article’s verification date, hemp has no more than 0.3% delta-9 THC on a dry-weight basis. Qualifying hemp is excluded from the Controlled Substances Act’s marijuana definition. That exclusion is not FDA approval of every product made from the plant. [3,4]

Nor does the definition establish a universal safe dose. A percentage-by-weight threshold and an amount per package measure different things. Claims that any product below 0.3% is automatically lawful everywhere ignore other federal requirements and state restrictions.

What the enacted hemp amendment actually changes

Section 781 of Public Law 119-37, signed November 12, 2025, narrows the federal definition. Its text originally provided an effective date 365 days after enactment. The amendment introduces a total THC standard, including THCA, rather than delta-9 THC alone, and expressly includes defined industrial-hemp uses. [1]

It also excludes specified cannabinoid products. Among them are products containing cannabinoids incapable of being naturally produced by cannabis, and products containing naturally producible cannabinoids synthesized or manufactured outside the plant. These are distinct statutory categories, not interchangeable shorthand for every extracted cannabinoid.

For final hemp-derived cannabinoid products, another exclusion covers more than 0.4 milligrams per container, combined, of total THC including THCA and specified other cannabinoids with similar effects. This is not a per-serving allowance or a limit on CBD itself. Nevertheless, it could affect CBD preparations containing small amounts of THC. Intermediate products have separate provisions. [1,3]

The crucial update is Public Law 119-103, enacted September 2, 2026. Section 2019 delays most of these amendments until December 11, 2026. The exclusions for intermediate and final products containing cannabinoids not capable of being naturally produced by cannabis remain scheduled for November 12. The broader total-THC standard and final-product threshold are among the provisions postponed to December 11. Neither future stage should be reported as operative on November 4. [2,3]

These are enacted changes with future application, not merely proposals. By contrast, H.R.7024, proposing a further two-year delay, is still listed as introduced on Congress.gov. Its proposed timetable is not law. [9]

Federal marijuana rules also changed—but not into general legalization

It is no longer accurate to say without qualification that all marijuana remains federally in Schedule I. An April 2026 final rule placed FDA-approved products containing marijuana and marijuana subject to qualifying state medical-marijuana licenses in Schedule III, within a defined federal framework. [5]

That does not authorize ordinary recreational commerce. DOJ’s October 30 announcement, updated November 3, describes federal registrations for qualifying medical dispensaries and explicitly says state licensure alone does not automatically grant federal registration. Marijuana outside the order’s scope remains subject to Schedule I controls; broader rescheduling is a separate proceeding. [6]

Consequently, a state authorization, a hemp classification and a federal controlled-substance registration answer different questions. None should be substituted for the others.

FDA: food and supplements have their own restrictions

FDA’s published position remains that CBD products are excluded from the federal definition of a dietary supplement. Calling a bottle a “supplement” does not overcome that exclusion. The agency also says introducing food with added CBD into interstate commerce is prohibited under the applicable food-and-drug statute. This includes animal food. [4]

Hemp seed ingredients are a different issue. FDA has evaluated GRAS notices for hulled hemp seed, hemp seed protein powder and hemp seed oil for specified food uses. Those ingredients are not equivalent to adding CBD extract to a drink, and their status does not authorize CBD generally.

Cosmetics follow another framework: cannabis-derived ingredients are not categorically prohibited, but products must satisfy applicable safety and labeling requirements. Disease-treatment claims or intended effects on the body can bring drug requirements into play. A retail listing, laboratory certificate or state permit is not evidence of FDA approval. [4]

States, sales and transportation: three separate checks

USDA oversees hemp production through approved state and tribal plans and a federal licensing framework. Its production authorization is not a general license for downstream CBD retail products. [7]

States add their own requirements. New York, for example, requires cannabinoid-hemp retail licensing for online and in-person sales, and distributor permits for specified out-of-state products. Its regulator expressly distinguishes that program from marijuana licensing. A New York authorization does not settle federal food law or another state’s requirements. [8]

Transportation is narrower than permission to sell. USDA’s legal opinion explains the federal protection against states or tribes prohibiting transportation through their territory of hemp lawfully produced under qualifying programs. That protection is not a blanket right to market any CBD formulation at its destination. It should not be generalized to marijuana, international borders or every carrier’s policies. [10]

Scope and sources

This is public-interest reporting, not legal or medical advice or a product recommendation. It is not a 50-state survey. Future implementation, litigation and later legislation may change this account. The reviewed September CRS report said FDA’s required cannabinoid lists were unpublished; this review did not locate a later publication and does not resolve every implementation question.

All sources below were consulted November 4, 2026. Explore our US coverage and editorial standards.

1. Public Law 119-37, §781, November 12, 2025.
2. Public Law 119-103, §2019, September 2, 2026.
3. CRS: hemp definition and agricultural policy, September 28, 2026.
4. FDA: cannabis and CBD questions and answers.
5. Final scheduling rule, official Federal Register PDF, April 28, 2026.
6. DOJ: medical-marijuana registrations, updated November 3, 2026.
7. USDA: Hemp Production.
8. New York OCM: retailers and distributors.
9. Congress.gov: H.R.7024 status.
10. USDA General Counsel: hemp authorities and transportation, May 28, 2019.